Reza Zonozi

Reza Zonozi

Auto-generated profile, based on publicly available information

Reza Zonozi

Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
RZReza Zonozi
Reza Zonozi
LWLucy C. Walters
Lucy C. Walters
ASAaron Shulkin
Aaron Shulkin
VNVivek Naranbhai
Vivek Naranbhai
PNPravarut Nithagon
Pravarut Nithagon
GGGaurav D. Gaiha
Gaurav D. Gaiha
Individuals with primary and pharmacologic B cell deficiencies have high rates of severe disease and mortality from coronavirus disease 2019 (COVID-19), but the immune responses and clinical outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have yet to be fully defined. Here, we evaluate the cellular immune responses after both SARS-CoV-2 infection and vaccination in patients receiving the anti-CD20 therapy rituximab (RTX) and those with low B cell counts due to common variable immune deficiency (CVID) disease. Assessment of effector and memory CD4 + and CD8 + T cell responses to SARS-CoV-2 revealed elevated reactivity and proliferative capacity after both infection and vaccination in B cell–deficient individuals, particularly within the CD8 + T cell compartment, in comparison with healthy controls. Evaluation of clinical outcomes demonstrates that vaccination of RTX-treated individuals was associated with about 4.8-fold reduced odds of moderate or severe COVID-19 in the absence of vaccine-induced antibodies. Analysis of T cell differentiation demonstrates that RTX administration increases the relative frequency of naïve CD8 + T cells, potentially by depletion of CD8 + CD20 dim T cells, which are primarily of an effector memory or terminal effector memory (TEMRA) phenotype. However, this also leads to a reduction in preexisting antiviral T cell immunity. Collectively, these data indicate that individuals with B cell deficiencies have enhanced T cell immunity after both SARS-CoV-2 infection and vaccination that potentially accounts for reduced hospitalization and severe disease from subsequent SARS-CoV-2 infection.

1 December 2021 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
PDF file
RZReza Zonozi
Reza Zonozi
KLKaren Laliberte
Karen Laliberte
NHNoah R. Huizenga
Noah R. Huizenga
JRJillian K. Rosenthal
Jillian K. Rosenthal
AJAnushya Jeyabalan
Anushya Jeyabalan
JNJohn L. Niles
John L. Niles
Rationale & Objective B-cell depletion with rituximab has emerged as a first-line therapy for primary membranous nephropathy (MN). However, most patients do not achieve complete remission with rituximab monotherapy. In this case series, we report longer-term remission and relapse rates, anti-phospholipase A2 receptor (PLA2R) antibody levels, B-cell levels, and serious adverse events in patients with primary MN who received rituximab combined with an initial short course of low-dose oral cyclophosphamide and a course of rapidly tapered prednisone. Study Design Single-center retrospective case series. Setting & Participants 60 consecutive patients with primary MN treated with the combination of rituximab, low-dose cyclophosphamide, and prednisone at the Vasculitis and Glomerulonephritis Center at the Massachusetts General Hospital. Findings After treatment initiation, median follow-up was 38 (interquartile range [IQR], 25-62) months; 100% of patients achieved partial remission, defined as a urinary protein-creatinine ratio (UPCR) < 3 g/g and a 50% reduction from baseline, at a median of 3.4 months. By 2 years after treatment initiation, 83% achieved complete remission, defined as a UPCR < 0.3 g/g. The median time to complete remission was 12.4 months. Immunologic remission (defined by an anti-PLA2R titer < 14 RU/mL) was achieved by 86% and 100% of anti-PLA2R seropositive patients (n = 29) at 3 and 6 months, respectively, after treatment initiation. After 1 year, the median UPCR fell from 8.4 (IQR, 5.0-10.7) to 0.3 (IQR, 0.2-0.8) g/g (P < 0.001). No patient relapsed throughout the duration of B-cell depletion. Relapse occurred in 10% of patients at 2 years after the onset of B-cell reconstitution following the last rituximab dose. Over a combined follow-up time of 228 patient-years, 18 serious adverse events occurred. One death occurred unrelated to treatment or primary MN, and 1 patient progressed to kidney failure requiring kidney replacement therapy. Limitations Absence of a comparison group. Conclusions All patients with primary MN treated with combination therapy achieved partial remission and most achieved a durable complete remission with an acceptable safety profile.

29 December 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
RZReza Zonozi
Reza Zonozi
ZWZachary S. Wallace
Zachary S. Wallace
KLKaren Laliberte
Karen Laliberte
NHNoah R. Huizenga
Noah R. Huizenga
JRJillian M. Rosenthal
Jillian M. Rosenthal
JNJohn L. Niles
John L. Niles

11 December 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
RZReza Zonozi
Reza Zonozi
FCFrank B Cortazar
Frank B Cortazar
AJAnushya Jeyabalan
Anushya Jeyabalan
GSGabriel Sauvage
Gabriel Sauvage
PNPravarut Nithagon
Pravarut Nithagon
JNJohn L Niles
John L Niles
Objective To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis. Methods We conducted a prospective, single-centre, open-label, randomised controlled trial of patients with ANCA vasculitis in remission after completing at least 2 years of fixed-schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm, rituximab was reinfused upon significant rise in ANCA level. Evaluations were conducted every 3 months. The primary endpoint was clinical relapse, defined as a modified BVAS/WG >0 by 36 months. Secondary endpoints included serious adverse events (SAEs) and rituximab exposure. Results 115 patients were enrolled. Median follow-up time was 4.1 years (IQR 2.5–5.0). By Kaplan-Meier analysis, 4.1% (95% CI 1.0 to 15.6) of patients had a clinical relapse in the B cell arm, compared with 20.5% (95% CI 11.9 to 34.1) in the ANCA arm, at 3 years after study entry (log-rank p=0.045). Total SAEs, including infectious SAEs, and deaths did not differ. The number of SAEs due to COVID-19 was higher in the B cell arm (p=0.049). In the B cell arm, patients received a mean of 3.6 (SD 2.4) infusions (3.6 g) per person over the median study follow-up time of 4.1 years, compared with 0.5 (SD 1.4) infusions (0.5 g) per patient in the ANCA arm (p<0.001). Conclusions Rituximab dosed for B cell repopulation results in fewer clinical relapses than when dosed for a rise in ANCA level in maintenance of remission for ANCA vasculitis. Overall safety was equivalent; SAEs due to COVID-19 and rituximab exposure were higher with the B cell strategy. Trial registration number NCT02749292.

1 May 2021 in Kidney International Reports
Verified
Journal Article
Open access
OEOrhan Efe
Orhan Efe
LGLipika Goyal
Lipika Goyal
AGAralee Galway
Aralee Galway
AZAndrew X. Zhu
Andrew X. Zhu
JNJohn L. Niles
John L. Niles
RZReza Zonozi
Reza Zonozi

12 July 2021 in Kidney International Reports
Verified
Journal Article
Open access
PNPravarut Nithagon
Pravarut Nithagon
FCFrank Cortazar
Frank Cortazar
SSSujal I. Shah
Sujal I. Shah
AWAstrid Weins
Astrid Weins
KLKaren Laliberte
Karen Laliberte
RZReza Zonozi
Reza Zonozi